The BeAT Goes On: New Data on Improving Symptoms in HFrEF Patients Using Novel Device Therapy

Summary: Host: William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCPE <br> Guest: Georges Chahoud, MD, FACC, FAHA, FHFSA, FASE <br> Guest: Patrick J. McCann, MD <br> <p>Even with guideline-directed medical therapy, or GDMT, many patients with heart failure are limited in their daily activities, due to increasing symptoms and reduced functionality. However, new data from BeAT-HF, a clinical trial that examines the long-term effects of baroreflex activation therapy, or BAT, shows that BAT may provide patients with sustained and durable benefits in exercise capacity, functional status, and quality of life.</p>